Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis Suppurativa

Inclusion Criteria: * Moderate to Severe (Hurley Stage 2 or 3) Hidradenitis Suppurativa as determined by the PI Exclusion Criteria: * Uncontrolled hypertension (systolic blood pressure \[BP\] ≥135 mmHg and/or diastolic BP ≥85 mmHg), unstable angina, congestive heart failure of New York Heart Association classification III or IV, serious cardiac arrhythmia requiring treatment (exceptions: atrial fibrillation, paroxysmal supraventricular tachycardia) at screening. * History of myocardial infarction within 3 months prior to screening. * Shock or hypotension requiring vasoactive peptides, such as dopamine, norepinephrine, epinephrine, or dobutamine at screening or at randomization. * Renal function impairment with creatinine clearance \<30 mL/min at screening (estimated glomerular filtration rate will be calculated using the modification of diet in renal disease equation). * Liver function impairment with aspartate aminotransferase/alanine aminotransferase \>=3x the upper limit of normal or bilirubin \>2X the upper limit of normal at screening. * Neutrophil count \<1000/µL at screening. * History of an allergic reaction or hypersensitivity to the study treatment or any component of the study treatment formulation. * Has documented HIV infection or documented, active hepatitis B or hepatitis C infection. * Women lactating, pregnant or of childbearing potential who are not willing to avoid becoming pregnant during the study. * Individuals with concurrent use of systemic antibiotics/ oral retinoids/ systemic immunosuppressants (those with prior use of these medications must have conducted a washout period of 4 weeks or 5 half-lives of the drug, whichever is longer). * Any medical, psychological or social condition that, in the opinion of the Investigator, would jeopardize the health or well-being of the participant during any study procedures or the integrity of the data.